ALT and aspartate aminotransferase (AST) levels were measured using the α-ketoglutarate reaction (Roche,
|
|
- Mark Holt
- 6 years ago
- Views:
Transcription
1 Supplemental Methods Analytical determinations ALT and aspartate aminotransferase (AST) levels were measured using the α-ketoglutarate reaction (Roche, Basel, Switzerland). Glucose, triglyceride, total and high density lipoprotein (HDL) cholesterol concentrations were determined by enzymatic methods (Roche, Basel, Switzerland). The erythrocyte sedimentation rate (ESR) was measured automatically by the stopped-flow technique in a capillary microphotometer (Alifax Test 1 System). Plasma fibrinogen concentration and platelet count were determined by routine laboratory tests using Sysmex CA-7000 Automated Coagulation Analyzer, and Sysmex SE9500 (DASIT SpA, Milan, Italy), respectively. High sensitivity CRP levels were measured by automated instrument (CardioPhase hscrp, Milan, Italy). Albumin concentration was determined with a Alb2 kit on a Cobas C6000 analyzer (Roche Diagnostics, Milan, Italy). All others metabolites were measured by standard methods Real-Time RT-PCR Liver samples were stored at-80 C and distrupted/homogenized using a TissueRuptor apparatus (Qiagen, Milan, Italy) immediately before proceeding to nucleic acid extraction. Total RNA was extracted from treated and control HepG2 cells and from frozen liver samples using AllPrep DNA/RNA Micro Kit (Qiagen, Milan, Italy), reverse transcribed and analyzed by quantitative Real-Time PCR technique using commercial Assays-on-Demand kits (all Applied Biosystems, Foster City, CA) according to the manufacturer s protocol and normalized to housekeeping 18S gene. All reactions were performed in duplicate. Relative gene expression was calculated by using the comparative CT method. Definitions Type 2 diabetes was diagnosed according to the American Diabetes Association (ADA) criteria (1). The metabolic syndrome was defined according to the criteria of the consensus statement released in 2009 (2). Using this definition, a subject has metabolic syndrome if he or she meets three or more of the following criteria: 1) waist circumference >102 cm in men and >88 cm in women), 2) triglyceride >150 mg/dl, 3) HDL <40 mg/dl in men and <50 mg/dl in women, 4) blood pressure >130/85 mmhg, and 5) fasting glucose >100 mg/dl. The diagnosis of NAFLD was based on chronically elevated Alanine aminotransferase (ALT) for at least 6 months, alcohol consumption of <20 g/day in the year before liver biopsy, and evaluated by a
2 questionnaire, steatosis (>5% of hepatocytes) at histology with or without necroinflammation and/or fibrosis, and absence of other causes of liver disease or mixed etiologies (excessive alcohol consumption, regular use of steatosis-inducing drugs, hepatitis C, hepatitis B, autoimmune liver disease, Wilson s disease, hemochromatosis, α1-antitrypsin deficiency). The NAFLD fibrosis score was calculated according to the following formula: x age (years) x body mass index (BMI kg/m 2 ) x impaired fasting glycemia or diabetes (yes=1, no= 0) x AST/ALT ratio x platelet (x10 9 /l x albumin (g/dl) (3). Two cutoff points (>0.676 and <-1.455) were used to divide the subjects in three groups: low risk of fibrosis (< ), intermediate risk of fibrosis ( ), and high risk of fibrosis (>0.676), as described by Angulo and colleagues (3). The Kleiner classification (4) was used to compute the NAFLD activity score (from 0 to 8, on a scale including separate scores for steatosis, lobular inflammation, and hepatocellular ballooning) and to stage fibrosis from 0 to 4 in subjects with biopsies. References 1. American Diabetes Association Standards of medical care in diabetes Diabetes Care 34 Suppl 1:S Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC, Jr Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120: Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, Enders F, Saksena S, Burt AD, Bida JP, Lindor K, Sanderson SO, Lenzi M, Adams LA, Kench J, Therneau TM, Day CP 2007 The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 45: Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ 2005 Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41:
3 Variables Supplementary Table 1 Anthropometric and biochemical characteristics of Cohort 1 Whole study subjects Low risk of fibrosis (< ) Intermediate risk of fibrosis ( ) High risk of fibrosis (>0.676) P P** P*** Gender (Male/Female) 122/99 39/36 71/47 12/ Age (yrs) 61.3± ± ±8.8 c 68.9±8.6 c <0.0001* <0.0001* <0.0001* BMI (kg/m 2 ) 31.2± ± ±5.1 c 35.6±8.1 c < < < Waist circumference (cm) 105±13 101±12 106±11 c 113±17 c < < < Fasting Glucose (mgl/dl) 119±48 98±23 125±47 c 153±71 c < Total cholesterol (mg/dl) 197±42 206±41 196±42 180± HDL (mg/dl) 48±14 49±15 47±13 44±10 a Triglycerides (mg/dl) 154±69 148±67 153±69 151± ALT (UI/l) 27±15 27±12 27±15 27± AST (UI/l) 25±14 22±7 23±10 31±18 b AST/ALT ratio 0.99± ± ± ±1.27 c < < < Platelet count (x10 9 /l) 237±64 275±61 228±55 c 174±44 c < < < Fibrinogen (mg/dl) 332±76 311±62 338±81 a 363±72 a hscrp (mg/l) 4.0± ± ±3.8 b 5.2±4.3 b ESR (mm/h) 12±10 9±7 12±9 a 19±13 c Albumin (g/dl) 4.43± ± ± ±0.28 c < < < IGF-1 (ng/ml) 135±54 150±54 131±53 a 116±53 a Metabolic syndrome - yes/no (% 162/59 (73.3%) 42/33 (56%) 94/24 (79.7%) 26/2 (92.9%) <
4 NFG/IFG/T2DM (n) 91/40/90 55/8/12 33/25/60 3/7/18 < Oral antidiabetic agents/insulin (n) 45/17 5/1 33/9 7/ Therapy with statins yes/no (%68/153 (30.8%) 18/57 (24%) 37/81 (31.4%) 13/15 (46.4%) Data are means ± SD. Categorical variables were compared by χ 2 test. P values refer to results after analyses with adjustment for age, and gender. The risk groups were established as described by Angulo and colleagues (3, Supplemental data ).*P values refer to results after analysis with adjustment for gender. **P values refer to results after analyses with adjustment for age, gender, metabolic syndrome, glucose lowering treatment and statin therapy. ***P values refer to results after analyses with adjustment for age, gender, type 2 diabetes, glucose lowering treatment and statin therapy. ESR = erythrocyte sedimentation rate; ALT =Alanine aminotransferase AST= aspartate aminotransferase NFG=normal fasting glucose; IFG= impaired fasting glucose; T2DM2= type 2 diabetes. a P<0.05 vs. Low risk of fibrosis group.; b P<0.01 vs. Low risk of fibrosis group.; c P< vs. Low risk of fibrosis group.
5 Supplementary Table 2 Anthropometric and biochemical characteristics of Cohort 2 Variables Age (yrs) 48.8±11.48 BMI (kg/m 2 ) 29.36±3.9 Fasting Glucose (mgl/dl) 101.5±27 Total cholesterol (mg/dl) 218±50 HDL (mg/dl) 53±24 Triglycerides (mg/dl) 153±71 ALT (UI/l) 72±44 AST (UI/l) 48±40 GGT 89±107 Data are means ± SD. ALT =Alanine aminotransferase AST= aspartate aminotransferase; GGT=gamma glutamyl-transferase
Background of the FIB-4 Index in Japanese Non-Alcoholic Fatty Liver Disease
ORIGINAL ARTICLE Background of the FIB-4 Index in Japanese Non-Alcoholic Fatty Liver Disease Takashi Wada and Mikio Zeniya Abstract Objective We investigated the distribution and characteristics of the
More informationNon-alcoholic fatty liver disease (NAFLD) is a
Original Article / Liver Hepatobiliary & Pancreatic Diseases International The association of non-alcoholic fatty liver disease and metabolic syndrome in a Chinese population Shou-Wu Lee, Teng-Yu Lee,
More informationNonalcoholic Fatty Liver Disease: Definitions, Risk Factors, and Workup
REVIEW REVIEW Nonalcoholic Fatty Liver Disease: Definitions, Risk Factors, and Workup Puneet Puri, M.B.B.S., M.D. and Arun J. Sanyal, M.B.B.S., M.D. Nonalcoholic fatty liver disease (NAFLD) is defined
More informationThe classical metabolic work-up, approved by the Ethics Committee of the Antwerp
SUPPLEMENTARY MATERIALS METHODS Metabolic work-up The classical metabolic work-up, approved by the Ethics Committee of the Antwerp University Hospital and requiring written informed consent, included a
More informationLIVER, PANCREAS, AND BILIARY TRACT
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2012;10:1028 1033 LIVER, PANCREAS, AND BILIARY TRACT Prevalence and Indicators of Portal Hypertension in Patients With Nonalcoholic Fatty Liver Disease FLAVIA D.
More informationChallenges in the Diagnosis of Steatohepatitis
The Bugaboos of Fatty Liver Disease: Ballooning and Fibrosis Hans Popper Hepatopathology Society Companion Meeting San Antonio, Tx March, 2017 David Kleiner, M.D., Ph.D. NCI/Laboratory of Pathology Challenges
More informationInternal and Emergency Medicine Official Journal of the Italian Society of Internal Medicine. ISSN Volume 8 Number 3
Hepatic Steatosis Index and Lipid Accumulation Product as middle-term predictors of incident metabolic syndrome in a large population sample: data from the Brisighella Heart Study Arrigo F. G. Cicero,
More informationCirrhosis Secondary to Nonalcoholic Fatty Liver Disease
Proceedings of UCLA Healthcare -VOLUME 19 (2015)- CLINICAL VIGNETTE Cirrhosis Secondary to Nonalcoholic Fatty Liver Disease Amruti Borad, D.O., and Michelle Sangalang, M.D. Introduction Primary care physicians
More informationWhat is NAFLD?.NASH? Presenter Disclosure Information. Learning Objectives. Case 1: Rob. Questions Pertinent to Rob
Presenter Disclosure Information 5 6pm Nonalcoholic Fatty Liver Disease (NAFLD): Another Obesity-Related Epidemic SPEAKER Elliot Tapper, MD The following relationships exist related to this presentation:
More informationHEP DART 2017, Kona, Hawaii
HEP DART 2017, Kona, Hawaii Rong Yu 1, Ke Xu 1, Jing Li 1, Tong Sun 1, Shengjiang Zhang 2, Jinhua Shao 2, Jin Sun 2, Qiong He 3, Jianwen Luo 3, Cheng Wang 4, Yudong Wang 4, Jing Chen 4, Vanessa Wu 4, George
More informationOriginal Article. Significance of Hepatic Steatosis in Chronic Hepatitis B Infection INTRODUCTION
Original Article Bhanthumkomol P, et al. THAI J GASTROENTEROL 2013 Vol. 14 No. 1 Jan. - Apr. 2013 29 Bhanthumkomol P 1 Charatcharoenwitthaya P 1 Pongpaiboon A 2 ABSTRACT Background: Significance of liver
More informationSimple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease
1 Liver Unit, Newcastle Upon Tyne Hospitals NHS Trust, Freeman Hospital, Newcastle upon Tyne, UK 2 Institute of Cellular Medicine, Faculty of Medical Sciences, Newcastle University, Newcastle Upon Tyne,
More informationThe effect of aerobic exercise on serum level of liver enzymes and liver echogenicity in patients with non-alcoholic fatty liver disease
Gastroenterology and Hepatology From Bed to Bench. 2013 RIGLD, Research Institute for Gastroenterology and Liver Diseases ORIGINAL ARTICLE The effect of aerobic exercise on serum level of liver enzymes
More informationCDHNF & NASPGHAN A Partnership for Research and Education for Children s Digestive and Nutritional Health
CDHNF & NASPGHAN A Partnership for Research and Education for Children s Digestive and Nutritional Health Obesity and NAFLD Definitions: Nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver
More informationNAFLD fibrosis score: A prognostic predictor for mortality and liver complications among NAFLD patients
Online Submissions: http://www.wjgnet.com/esps/ wjg@wjgnet.com doi:10.3748/wjg.v19.i8.1219 World J Gastroenterol 2013 February 28; 19(8): 1219-1229 ISSN 1007-9327 (print) ISSN 2219-2840 (online) 2013 Baishideng.
More informationAmerican Journal of Oral Medicine and Radiology
American Journal of Oral Medicine and Radiology e - ISSN - XXXX-XXXX ISSN - 2394-7721 Journal homepage: www.mcmed.us/journal/ajomr PREVALENCE OF NONALCOHOLIC FATTY LIVER DISEASE AMONG TYPE 2 DIABETIC POPULATION
More informationThe role of non-invasivemethods in evaluating liver fibrosis of patients with non-alcoholic steatohepatitis
The role of non-invasivemethods in evaluating liver fibrosis of patients with non-alcoholic steatohepatitis Objectives: Liver biopsy is the gold standard for diagnosing the extent of fibrosis in NAFLD/NASH;
More informationEFFECT OF ORAL SUPPLEMENTATION OF WHEY PROTEIN ISOLATE ON NON-ALCOHOLIC STEATOHEPATITIS PATIENTS
42 EFFECT OF ORAL SUPPLEMENTATION OF WHEY PROTEIN ISOLATE ON NON-ALCOHOLIC STEATOHEPATITIS PATIENTS Prasong Tienboon MD, PhD. 1, Taned Chitapanarux MD. 2, Suwalee Pojchamarnwiputh MD. 3, Donrawee Leelarungrayub
More informationNonalcoholic fatty liver disease (NAFLD) and nonalcoholic. Noninvasive Assessment of Nonalcoholic Fatty Liver Disease in Obese or Overweight Patients
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2012;10:1162 1168 Noninvasive Assessment of Nonalcoholic Fatty Liver Disease in Obese or Overweight Patients SVEN M. A. FRANCQUE,* AN VERRIJKEN, ILSE MERTENS, GUY
More informationNON-ALCOHOLIC FATTY LIVER DISEASE:
NON-ALCOHOLIC FATTY LIVER DISEASE: ROLE OF THE PRIMARY PROVIDER Archita P. Desai, MD Assistant Professor of Medicine University of Arizona 25 th Annual Southwestern Conference on Medicine Outline Pathophysiology
More informationNew discriminant score to predict the fibrotic stage of non-alcoholic steatohepatitis in Japan
Hepatol Int (215) 9:269 277 DOI 1.17/s1272-14-965-x ORIGINAL ARTICLE New discriminant score to predict the fibrotic stage of non-alcoholic steatohepatitis in Japan Yusuke Kawamura Kenji Ikeda Yasuji Arase
More informationThe histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies *
Journal of Hepatology 42 (2005) 132 138 www.elsevier.com/locate/jhep The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies * Leon
More informationTransient elastography in chronic liver diseases of other etiologies
4 Post Meeting A.I.S.F. Unmet Clinical Needs in Hepatology: New and upcoming diagnostic tools" Transient elastography in chronic liver diseases of other etiologies Dr. Vincenza Calvaruso Gastroenterologia
More informationCorrelation between bright echogenic liver, elevated liver enzymes and liver histology.
Original Article Correlation between bright echogenic liver, elevated liver enzymes and liver histology. Dr. Iqbal Murshed Kabir, Dr. Mahbub Alam, Dr. Mohammad Mahmuduzzaman, Dr. Abdullah Al Mamoon, Dr.
More informationNon-Alcoholic Fatty Liver Disease and Metabolic Syndrome in Type 2 Diabetes Mellitus Patients in Rajshahi Medical College Hospital
WELCOME Non-Alcoholic Fatty Liver Disease and Metabolic Syndrome in Type 2 Diabetes Mellitus Patients in Rajshahi Medical College Hospital Presented by DR. PRABIR MOHAN BASAK ASSISTANT PROFESSOR DEPARTMENT
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery
More informationPrevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus patients in a tertiary care hospital of Bihar
Original Research Article Prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus patients in a tertiary care hospital of Bihar Naresh Kumar 1, Jyoti Kumar Dinkar 2*, Chandrakishore
More informationRelationship among biomarkers of iron metabolism and severity of underlying nonalcoholic steatohepatitis (NASH)
Original Article Page 1 of 8 Relationship among biomarkers of iron metabolism and severity of underlying nonalcoholic steatohepatitis (NASH) Marise Pereira da Silva 1, Carlos Antonio Caramori 2, Cilmery
More informationEffect of lifetime alcohol consumption on the histological severity of non-alcoholic fatty liver disease
Liver International ISSN 1478-3223 METABOLIC AND STEATOHEPATITIS Effect of lifetime alcohol consumption on the histological severity of non-alcoholic fatty liver disease Hellan K. Kwon 1, Joel K. Greenson
More informationPancreatic exocrine insufficiency: a rare cause of nonalcoholic steatohepatitis
Pancreatic exocrine insufficiency: a rare cause of nonalcoholic steatohepatitis Naoki Tanaka 1, Akira Horiuchi 2, Takahide Yokoyama 3, Shigeyuki Kawa 1, and Kendo Kiyosawa 1 1 Department of Gastroenterology,
More informationAlthough nonalcoholic fatty liver disease (NAFLD) Decreased Survival of Subjects with Elevated Liver Function Tests During a 28-Year Follow-Up
Decreased Survival of Subjects with Elevated Liver Function Tests During a 28-Year Follow-Up Cecilia Söderberg, 1 Per Stål, 2,3 Johan Askling, 1 Hans Glaumann, 3 Greger Lindberg, 3 Joel Marmur, 3 and Rolf
More informationABNORMAL LIVER FUNCTION TESTS. Dr Uthayanan Chelvaratnam Hepatology Consultant North Bristol NHS Trust
ABNORMAL LIVER FUNCTION TESTS Dr Uthayanan Chelvaratnam Hepatology Consultant North Bristol NHS Trust INTRODUCTION Liver function tests Cases Non invasive fibrosis measurement Questions UK MORTALITY RATE
More informationNAFLD and NASH: The Not-So-New Kids on the Block
NAFLD and NASH: The Not-So-New Kids on the Block Mary E. Rinella, MD Associate Professor of Medicine Feinberg School of Medicine Northwestern University Chicago, Illinois This program is supported by an
More informationChemistry Reference Ranges and Critical Values
Alanine Aminotransferase (ALT, SGPT) 3-9 years 9-18 years 1-9 years 9-18 years 10-30 U/L 10-30 U/L 10-20 U/L Albumin 0-6 days 6 days - 37 months 37 months - 7 years 7-20 years 2.6-3.6 g/dl 3.4-4.2 g/dl
More informationChemistry Reference Ranges and Critical Values
Alanine Aminotransferase (ALT, SGPT) 3-9 years 9-18 years 1-9 years 9-18 years 10-25 U/L 10-35 U/L 10-30 U/L 10-25 U/L 10-30 U/L 10-35 U/L 10-25 U/L 10-35 U/L 10-25 U/L 10-20 U/L 10-35 U/L Albumin 0-6
More informationAt Least 1 in 5 Patients in Your Practice Have Fatty Liver
At Least 1 in 5 Patients in Your Practice Have Fatty Liver What Can You Tell Your Patients Magnus McLeod MD FRCPC Assistant Professor Dalhousie University 30-NOV-2017 NAFLD Non-Alcoholic Fatty Liver Disease
More informationDisclosure. Objectives. Smash the Nash: A practical approach to fatty liver disease
Smash the Nash: A practical approach to fatty liver disease Bruce D. Askey, MS, ANP-BC Associate Lecturer North Andover, MA Adult Nurse Practitioner Dept. of Hepatology/Gastroenterology Guthrie Clinic
More informationIn Search of New Biomarkers for Nonalcoholic Fatty Liver Disease
REVIEW In Search of New Biomarkers for Nonalcoholic Fatty Liver Disease Ting-Ting Chan, M.R.C.P., and Vincent Wai-Sun Wong, M.D. Nonalcoholic fatty liver disease (NAFLD) affects 15% to 40% of the general
More informationAlpha fetoprotein levels and its relationship with histopathological findings in patients with non-alcoholic fatty liver disease
European Review for Medical and Pharmacological Sciences Alpha fetoprotein levels and its relationship with histopathological findings in patients with non-alcoholic fatty liver disease M. KARA 1, H. GENC
More informationThe Absence of Obstructive Sleep Apnea May Protect against Non- Alcoholic Fatty Liver in Patients Undergoing Bariatric Surgery
The Absence of Obstructive Sleep Apnea May Protect against Non- Alcoholic Fatty Liver in Patients Undergoing Bariatric Surgery The Harvard community has made this article openly available. Please share
More informationAssessment of NAFLD cases and its correlation to BMI and metabolic syndrome in healthy blood donors in Kerman
Gastroenterology and Hepatology From Bed to Bench 2012 RIGLD, Research Institute for Gastroenterology and Liver Diseases ORIGINAL ARTICLE Assessment of NAFLD cases and its correlation to BMI and metabolic
More informationManaging abnormal LFTs in Primary care
Managing abnormal LFTs in Primary care Summary guideline, April 2015 Sally Hull, Lucy Carter Managing abnormal LFTs in Primary care Draft guideline written by Dr Sally Hull and Dr Lucy Carter at CEG, with
More informationPROGRESSION TO FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) THE VALUE OF NONINVASIVE MARKERS
Supplement 1/2015, 4 th ISAA PROGRESSION TO FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) THE VALUE OF NONINVASIVE MARKERS Denisa DOBRIN 1, Tiberiu Ioan NANEA 2, Cristian Mihai POMOHACI
More informationHepatocellular carcinoma is the most common liver-related complication in patients with histopathologically-confirmed NAFLD in Japan
Akuta et al. BMC Gastroenterology (2018) 18:165 https://doi.org/10.1186/s12876-018-0900-1 RESEARCH ARTICLE Open Access Hepatocellular carcinoma is the most common liver-related complication in patients
More informationNonalcoholic fatty liver disease (NAFLD) is the most common
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2008;6:1249 1254 Cytokeratin 18 Fragment Levels as a Noninvasive Biomarker for Nonalcoholic Steatohepatitis in Bariatric Surgery Patients DIMA L. DIAB,* LISA YERIAN,
More informationJournal of Adolescent Health 42 (2008) Original article. Manuscript received September 5, 2007; manuscript accepted November 27, 2007
Journal of Adolescent Health 42 (2008) 543 548 Original article Presence of the Metabolic Syndrome in Obese Adolescents Predicts Impaired Glucose Tolerance and Nonalcoholic Fatty Liver Disease Kathy A.
More informationSupplementary Table 1. The distribution of IFNL rs and rs and Hardy-Weinberg equilibrium Genotype Observed Expected X 2 P-value* CHC
Supplementary Table 1. The distribution of IFNL rs12979860 and rs8099917 and Hardy-Weinberg equilibrium Genotype Observed Expected X 2 P-value* CHC rs12979860 (n=3129) CC 1127 1145.8 CT 1533 1495.3 TT
More informationGuidelines for the diagnosis and management of nonalcoholic fatty liver disease: Update 2010
doi: 10.1111/j.1751-2980.2010.00476.x Consensus report Guidelines for the diagnosis and management of nonalcoholic fatty liver disease: Update 2010 (Published in Chinese on Chinese Journal of Hepatology
More informationNONALCOHOLIC FATTY LIVER DISEASE. Non-Alcoholic Fatty Liver Disease (NAFLD) Primary NAFLD. April 13, 2012
NONALCOHOLIC FATTY LIVER DISEASE Kiran Bambha, MD University of Colorado Denver April 13, 2012 Non-Alcoholic Fatty Liver Disease (NAFLD) Primary NAFLD Simple Steatosis Fatty hepatocytes Intracellular fat
More informationN O T P R I N T A B L E. Plasminogen activator inhibitor-1 and thrombin activatable fibrinolysis inhibitor levels in non-alcoholic steatohepatitis
J. Endocrinol. Invest. 30: 810-819, 2007. Plasminogen activator inhibitor-1 and thrombin activatable fibrinolysis inhibitor levels in non-alcoholic steatohepatitis S. Yener 1, M. Akarsu 2, T. Demir 1,
More informationInternational Journal of Current Research and Academic Review ISSN: Volume 3 Number 9 (September-2015) pp
International Journal of Current Research and Academic Review ISSN: 2347-3215 Volume 3 Number 9 (September-2015) pp. 243-251 www.ijcrar.com Effect of Ursodeoxycholic acid on lipid profile in NAFLD patients
More informationORIGINAL ARTICLE. Both these authors contributed equally to this study. Liver International ISSN
Liver International ISSN 1478-3223 ORIGINAL ARTICLE The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients
More informationNonalcoholic steatohepatitis (NASH) is a chronic. Randomized Controlled Trial Testing the Effects of Weight Loss on Nonalcoholic Steatohepatitis
Randomized Controlled Trial Testing the Effects of Weight Loss on Nonalcoholic Steatohepatitis Kittichai Promrat, 1,4 David E. Kleiner, 3 Heather M. Niemeier, 2,5 Elizabeth Jackvony, 2 Marie Kearns, 2
More informationORIGINAL PAPERS ABSTRACT INTRODUCTION
ORIGINAL PAPERS Analytical, anthropometric and dietary factors associated with the development of fibrosis in patients with nonalcoholic fatty liver disease Sara Gómez-de-la-Cuesta 1, Rocío Aller-de-la-Fuente
More informationSupplementary Table 1. Criteria for selection of normal control individuals among healthy volunteers
Supplementary Table 1. Criteria for selection of normal control individuals among healthy volunteers Medical parameters Cut-off values BMI (kg/m 2 ) 25.0 Waist (cm) (Men and Women) (Men) 85, (Women) 90
More informationtage Percent Total & over Total & over Men Women Men Women
Paul Angulo, MD, FACG, AGAF Professor of Medicine, Section Chief of Hepatology Division i i of Digestive i Diseases and Nutrition i University of Kentucky Medical Center Lexington, KY Paul Angulo, MD University
More informationUpdate on Non-Alcoholic Fatty Liver Disease. Timothy R. Morgan, MD Chief, Hepatology, VA Long Beach Professor of Medicine, UCI
Update on Non-Alcoholic Fatty Liver Disease Timothy R. Morgan, MD Chief, Hepatology, VA Long Beach Professor of Medicine, UCI February 3, 2018 Disclosure Clinical trials: Genfit Speaker s Bureau: none
More informationAAIM: GI Workshop Follow Up to Case Studies. Non-alcoholic Fatty Liver Disease Ulcerative Colitis Crohn s Disease
AAIM: GI Workshop Follow Up to Case Studies Non-alcoholic Fatty Liver Disease Ulcerative Colitis Crohn s Disease Daniel Zimmerman, MD VP and Medical Director, RGA Global October 2015 Non-alcoholic Fatty
More informationTables of Normal Values (As of February 2005)
Tables of Normal Values (As of February 2005) Note: Values and units of measurement listed in these Tables are derived from several resources. Substantial variation exists in the ranges quoted as normal
More informationNON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND NON- ALCOHOLIC STEATOHEPATITIS (NASH) IN ASIAN-PACIFIC REGION
SL 2-1 NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND NON- ALCOHOLIC STEATOHEPATITIS (NASH) IN ASIAN-PACIFIC REGION Mikio KAJIHARA 1,3, Yoshinori HORIE 2,3, Hiromasa ISHII 3 1 Tokyu Hospital, 2 Eiju General
More information/ FIB4 Index , simple steatosis. FIB4 Index. FIB4 Index. FIB4 Index FIB4 Index. Sterling FIB4 Index. FIB4 Index AST AST ALT
原 著 29 34-41, 2014 FIB4 Index 1 1 1 1 2 1 1 FIB4 Index FIB4 Index cut off 2.67 2.67 12,059 FIB4 IndexFIB4 Index 2.67 / FIB4 Index AST ALT FIB4 Index 2.67 161 1.3% FIB4 Index 5 FIB4 Index 1.1 5 1.6 FIB4
More informationIntroduction 5/2/2013 IRON RELATED GENES AND OXIDATIVE STRESS IN NON- ALCOHOLIC STEATOHEPATITIS. Iron Physiology. Iron Physiology
// IRON RELATED GENES AND OXIDATIVE STRESS IN NON- ALCOHOLIC STEATOHEPATITIS DIANA MOYA, MD PEDIATRIC GASTROENTEROLOGY FELLOW DIGESTIVE DISEASES & NUTRITION CENTER MAY,. Iron Physiology. /NAFLD. Iron Metabolism
More informationPredictive Factors for Nonalcoholic Steatohepatitis (NASH) in Patients with Nonalcoholic Fatty Liver Disease (NAFLD)
Predictive Factors for Nonalcoholic Steatohepatitis (NASH) in Patients with Nonalcoholic Fatty Liver Disease (NAFLD) Carmen Fierbinteanu-Braticevici 1, Cristian Baicus 2, Laura Tribus 1, Raluca Papacocea
More informationAssociation between Raised Blood Pressure and Dysglycemia in Hong Kong Chinese
Diabetes Care Publish Ahead of Print, published online June 12, 2008 Raised Blood Pressure and Dysglycemia Association between Raised Blood Pressure and Dysglycemia in Hong Kong Chinese Bernard My Cheung,
More informationNON-ALCOHOLIC STEATOHEPATITIS AND NON-ALCOHOLIC FATTY LIVER DISEASES
NON-ALCOHOLIC STEATOHEPATITIS AND NON-ALCOHOLIC FATTY LIVER DISEASES Preface Zobair M. Younossi xiii Epidemiology and Natural History of NAFLD and NASH 1 Janus P. Ong and Zobair M. Younossi Understanding
More informationOriginal Article. Nonalcoholic fatty liver disease in severely obese individuals: The influence of bariatric surgery. Introduction
364 Annals of Annals Hepatology of Hepatology 2008; 7(4): 7(4) October-December: 2008: 364-368 364-368 medigraphic Artemisa en línea Original Article Annals of Hepatology Nonalcoholic fatty liver disease
More informationNAFLD AND TYPE 2 DIABETES
NAFLD AND TYPE 2 DIABETES Sonia Caprio, MD STOPNASH Symposium on the Origin and Pathways of Nonalcoholic Steatohepatitis Washington 7, 215 Global Projection of Diabetes Hossain P et al. N Engl J Med 27;356:213
More informationDevelopment and validation of a simple index system to predict nonalcoholic fatty liver disease
The Korean Journal of Hepatology 2011;17:19-26 DOI: 10.3350/kjhep.2011.17.1.19 Original Article Development and validation of a simple index system to predict nonalcoholic fatty liver disease Young Jin
More informationFasting Glucose, Obesity, and Metabolic Syndrome as Predictors of Type 2 Diabetes: The Cooper Center Longitudinal Study
Fasting Glucose, Obesity, and Metabolic Syndrome as Predictors of Type 2 Diabetes: The Cooper Center Longitudinal Study Laura F. DeFina, MD,* Gloria Lena Vega, PhD,Þ David Leonard, PhD,Þ and Scott M. Grundy,
More informationEffects of probiotics in the treatment of alcoholic hepatitis: randomized controlled multicenter study
Effects of probiotics in the treatment of alcoholic hepatitis: randomized controlled multicenter study Lactobacillus subtilis/streptococcus faecium Lactobacillus rhamnosus R0011/acidophilus R0052 Ki Tae
More informationIs increased red cell distribution width an indicating marker of nonalcoholic steatohepatitis and fibrotic stage?
Online Submissions: http://www.wjgnet.com/esps/ bpgoffice@wjgnet.com doi:10.3748/wjg.v19.i42.7412 World J Gastroenterol 2013 November 14; 19(42): 7412-7418 ISSN 1007-9327 (print) ISSN 2219-2840 (online)
More informationEVALUATION OF ABNORMAL LIVER TESTS
EVALUATION OF ABNORMAL LIVER TESTS MIA MANABAT DO PGY6 MOA 119 TH ANNUAL SPRING SCIENTIFIC CONVENTION MAY 19, 2018 EVALUATION OF ABNORMAL LIVER TESTS Review of liver enzymes vs liver function tests Clinical
More informationAssociation of the serum uric acid level with liver histology in biopsy proven non alcoholic fatty liver disease
188 Association of the serum uric acid level with liver histology in biopsy proven non alcoholic fatty liver disease QIAN HUANG 1, JIANHUA YU 2, XIANTU ZHANG 3, SHOURONG LIU 4 and YANYAN GE 5 Departments
More informationLaboratory analysis of the obese child recommendations and discussion. MacKenzi Hillard May 4, 2011
Laboratory analysis of the obese child recommendations and discussion MacKenzi Hillard May 4, 2011 aka: What to do with Fasting Labs The Obesity Epidemic The prevalence of obesity in adolescents has tripled
More informationNAFLD: evidence-based management. Curso de residentes AEEH Salvador Augustin, MD Liver Unit Vall d Hebron Hospital Barcelona, Spain
NAFLD: evidence-based management Curso de residentes AEEH 2017 Salvador Augustin, MD Liver Unit Vall d Hebron Hospital Barcelona, Spain Clinical case - 55 yo female - Sent for incidental steatosis at abdominal
More informationMetabolic Syndrome. Bill Roberts, M.D., Ph.D. Professor of Pathology University of Utah
Metabolic Syndrome Bill Roberts, M.D., Ph.D. Professor of Pathology University of Utah Objectives Be able to outline the pathophysiology of the metabolic syndrome Be able to list diagnostic criteria for
More informationOne-Year Intense Nutritional Counseling Results in Histological Improvement in Patients with Nonalcoholic Steatohepatitis: A Pilot Study
American Journal of Gastroenterology ISSN 0002-9270 C 2005 by Am. Coll. of Gastroenterology doi: 10.1111/j.1572-0241.2005.41334.x Published by Blackwell Publishing One-Year Intense Nutritional Counseling
More informationNew Discriminant Method for Identifying the Aggressive Disease Phenotype of Non-alcoholic Fatty Liver Disease
ORIGINAL ARTICLE New Discriminant Method for Identifying the Aggressive Disease Phenotype of Non-alcoholic Fatty Liver Disease Yusuke Kawamura 1,2, Kenji Ikeda 1,2, Yasuji Arase 1,2, Shunichiro Fujiyama
More informationNoninvasive Diagnosis and Staging of Liver Disease. Naveen Gara, MD
Noninvasive Diagnosis and Staging of Liver Disease Naveen Gara, MD Outline Brief overview of the anatomy of liver Liver-related lab tests Chronic liver disease progression Estimation of liver fibrosis
More informationNASH UPDATE ON DIAGNOSTICS AND THERAPY. Arun J Sanyal MBBS, MD Virginia Commonwealth University School of Medicine
NASH UPDATE ON DIAGNOSTICS AND THERAPY Arun J Sanyal MBBS, MD Virginia Commonwealth University School of Medicine Conflicts of interest Salaried employee: of VCU Member of Board: McGuire VA Research Institute,
More informationBeneficial Effects of Pentoxifylline on Hepatic Steatosis, Fibrosis and Necroinflammation in Patients With Non-alcoholic Steatohepatitis
Beneficial Effects of Pentoxifylline on Hepatic Steatosis, Fibrosis and Necroinflammation in Patients With Non-alcoholic Steatohepatitis Sanjaya K. Satapathy; Puja Sakhuja; Veena Malhotra; Barjesh C. Sharma;
More informationEASL EASD EASO Clinical practice guidelines for the management of nonalcoholic fatty liver disease.
Commentary. EASL EASD EASO Clinical practice guidelines for the management of nonalcoholic fatty liver disease. Christopher D. Byrne 1,2, Giovanni Targher 3 1 Nutrition and Metabolism, Faculty of Medicine,
More informationJMSCR Vol 06 Issue 12 Page December 2018
www.jmscr.igmpublication.org Impact Factor (SJIF): 6.379 Index Copernicus Value: 79.54 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v6i12.63 Insulinemic Status and Nonalcoholic
More informationOpen-labeled pilot study of cysteine-rich whey protein isolate supplementation for nonalcoholic steatohepatitis patients
doi:10.1111/j.1440-1746.2009.05865.x HEPATOLOGY_5865 1045..1050 Open-labeled pilot study of cysteine-rich whey protein isolate supplementation for nonalcoholic steatohepatitis patients Taned Chitapanarux,*
More informationNonalcoholic fatty liver disease (NAFLD) is considered
ORIGINAL ARTICLE High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels Paola Portillo-Sanchez, Fernando Bril, Maryann Maximos,
More informationKeywords: NASH, insulin resistance, metformin, histopathology. William W. Shields, K.E. Thompson, G.A. Grice, S.A. Harrison and W.J.
Therapeutic Advances in Gastroenterology Original Research The effect of metformin and standard therapy versus standard therapy alone in nondiabetic patients with insulin resistance and nonalcoholic steatohepatitis
More information広島大学学術情報リポジトリ Hiroshima University Institutional Repository
広島大学学術情報リポジトリ Hiroshima University Institutional Repository Title Auther(s) Citation Issue Date DOI Atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis
More informationAlarming high levels of transaminases in non insulin dependent diabetes mellitus
Original article: Alarming high levels of transaminases in non insulin dependent diabetes mellitus *Ekta Chitkara Department of Applied Medical Sciences, Lovely Professional University, Punjab, India *Corresponding
More informationA Modification of the Brunt System for Scoring Liver Histology of Patients with Non-Alcoholic Fatty Liver Disease
Arch Iran Med 2010; 13 (1): 38 44 Original Article A Modification of the Brunt System for Scoring Liver Histology of Patients with Non-Alcoholic Fatty Liver Disease Shahin Merat MD*, Farzaneh Khadem-Sameni
More informationSerum proteomic analysis revealed diagnostic value of hemoglobin for nonalcoholic fatty liver disease
Serum proteomic analysis revealed diagnostic value of hemoglobin for nonalcoholic fatty liver disease Chaohui Yu 1,, Chengfu Xu 1,, Lei Xu 1, Jiekai Yu 2, Min Miao 3, Youming Li 1, 1 Department of Gastroenterology,
More informationPrevalence of non-alcoholic fatty liver disease (NAFLD) in type 2 diabetic patients in correlation with coronary artery disease
Original Research Article Prevalence of non-alcoholic fatty liver disease (NAFLD) in type 2 diabetic patients in correlation with coronary artery disease Ramulu Pulimaddi 1*, Amruth Rao Parveda 2, Dhanunjaya
More informationPrevalence of non-alcoholic fatty liver disease in type-2 diabetes mellitus patients
International Journal of Research in Medical Sciences Patel H et al. Int J Res Med Sci. 2018 Apr;6(4):1322-1326 www.msjonline.org pissn 2320-6071 eissn 2320-6012 Original Research Article DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20181290
More informationRelationship between Serum Iron Indices and Hepatic Iron Quantitation in Patients with Fatty Liver Disease
International Journal of Business, Humanities and Technology Vol. 2 No. 5; August 2012 Relationship between Serum Iron Indices and Hepatic Iron Quantitation in Patients with Fatty Liver Disease Dr. Mariana
More informationCase #1. Digital Slides 11/6/ year old woman presented with abnormal liver function tests. Liver Biopsy to r/o autoimmune hepatitis
45 year old woman presented with abnormal liver function tests Liver Biopsy to r/o autoimmune hepatitis Further down. ANA 1: 160; ASMA 1:80 ANA 1: 160; ASMA 1:80 IgG = 14.5 g/l (upper normal range: 16)
More informationNon alcoholic fatty liver and Non alcoholic Steatohepatitis. By Dr. Seham Seif
Non alcoholic fatty liver and Non alcoholic Steatohepatitis By Dr. Seham Seif Definition NAFL describe a common clinicopathological conditions characterized by significant lipid deposition in the hepatocytes
More informationAbnormal serum alanine transaminase levels in adult patients with type 1 diabetes
Abnormal serum alanine transaminase levels in adult patients with type 1 diabetes Gautam Das 1 MD, MRCP (Diabetes and Endocrinology), FRCP, FACE (USA), Consultant in Endocrinology John Geen 2,3 MSc, PhD,
More informationNon-Alcoholic Fatty Liver Disease (NAFLD)
HEPATO-PANCREATO-BILIARY STOMACH CANCER PROGRAM Non-Alcoholic Fatty Liver Disease (NAFLD) Steatosis and Non-Alcoholic Steatohepatitis (NASH) Management Recommendations UCSF Fresno Department of Surgery
More informationDepartment of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam , Republic of Korea 2)
Endocrine Journal 2013, 60 (12), 1295-1301 Or i g i n a l The association between non-alcoholic fatty liver disease and carotid atherosclerosis in subjects with within-reference range alanine aminotransferase
More informationDesign and Validation of a Histological Scoring System for Nonalcoholic Fatty Liver Disease
Design and Validation of a Histological Scoring System for Nonalcoholic Fatty Liver Disease David E. Kleiner, 1 Elizabeth M. Brunt, 2 Mark Van Natta, 3 Cynthia Behling, 4 Melissa J. Contos, 5 Oscar W.
More informationPostmenopausal women are at an increased risk
AMERICAN ASSOCIATION FOR THE STUDY OFLIVERD I S E ASES HEPATOLOGY, VOL. 64, NO. 1, 2016 A Longer Duration of Estrogen Deficiency Increases Fibrosis Risk Among Postmenopausal Women With Nonalcoholic Fatty
More information